Simply because individuals that carry the APOE e4 gene variant seem to have a larger risk of serious problems, the FDA suggests remaining tested for the gene variant before starting treatment with lecanemab or donanemab. No new protection alerts ended up noticed with continued lecanemab treatment. Soon after the 1st https://jimix864uem3.wikikali.com/user